• Publications
  • Influence
Comprehensive genomic profiles of small cell lung cancer
TLDR
This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer. Expand
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
TLDR
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia, and the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytes. Expand
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
TLDR
The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy. Expand
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
TLDR
Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil. Expand
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
TLDR
This study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background. Expand
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working
TLDR
The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice is provided. Expand
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
TLDR
F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients. Expand
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
TLDR
The results implicate Src family kinases as therapeutic targets in Ph+ B-ALL and suggest that simultaneous inhibition of Src and Bcr-Abl kinases may benefit individuals with Ph+ acute leukemia. Expand
Chronic lymphocytic leukaemia
TLDR
This Seminar reviews the recent progress in the management of chronic lymphocytic leukaemia and highlights new questions surrounding the optimal disease management. Expand
Multiple myeloma: increasing evidence for a multistep transformation process.
TLDR
This review intends to propose a model of a stepwise malignant transformation during MM pathogenesis, and diagnostic and therapeutic implications of this model will be discussed. Expand
...
1
2
3
4
5
...